These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 29190892)

  • 21. Effects of long non-coding RNA H19 and microRNA let7a expression on thyroid cancer prognosis.
    Liu N; Zhou Q; Qi YH; Wang H; Yang L; Fan QY
    Exp Mol Pathol; 2017 Aug; 103(1):71-77. PubMed ID: 28655518
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A long non-coding RNA contributes to doxorubicin resistance of osteosarcoma.
    Zhang CL; Zhu KP; Shen GQ; Zhu ZS
    Tumour Biol; 2016 Feb; 37(2):2737-48. PubMed ID: 26408180
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Icariin enhances cytotoxicity of doxorubicin in human multidrug-resistant osteosarcoma cells by inhibition of ABCB1 and down-regulation of the PI3K/Akt pathway.
    Wang Z; Yang L; Xia Y; Guo C; Kong L
    Biol Pharm Bull; 2015; 38(2):277-84. PubMed ID: 25747987
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The long non-coding RNA 91H increases aggressive phenotype of breast cancer cells and up-regulates H19/IGF2 expression through epigenetic modifications.
    Vennin C; Spruyt N; Robin YM; Chassat T; Le Bourhis X; Adriaenssens E
    Cancer Lett; 2017 Jan; 385():198-206. PubMed ID: 27780718
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Visfatin mediates doxorubicin resistance in human colorectal cancer cells via up regulation of multidrug resistance 1 (MDR1).
    Yan X; Zhao J; Zhang R
    Cancer Chemother Pharmacol; 2017 Aug; 80(2):395-403. PubMed ID: 28667355
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Molecular mechanisms of loss of beta 2-microglobulin expression in drug-resistant breast cancer sublines and its involvement in drug resistance.
    Ogretmen B; McCauley MD; Safa AR
    Biochemistry; 1998 Aug; 37(33):11679-91. PubMed ID: 9709006
    [TBL] [Abstract][Full Text] [Related]  

  • 27. c-Myc-activated long non-coding RNA H19 downregulates miR-107 and promotes cell cycle progression of non-small cell lung cancer.
    Cui J; Mo J; Luo M; Yu Q; Zhou S; Li T; Zhang Y; Luo W
    Int J Clin Exp Pathol; 2015; 8(10):12400-9. PubMed ID: 26722426
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Transcriptome analysis of long noncoding RNAs reveals their potential roles in anthracycline-induced cardiotoxicity.
    Nguyen N; Souza T; Kleinjans J; Jennen D
    Noncoding RNA Res; 2022 Jun; 7(2):106-113. PubMed ID: 35415316
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Src/STAT3-dependent heme oxygenase-1 induction mediates chemoresistance of breast cancer cells to doxorubicin by promoting autophagy.
    Tan Q; Wang H; Hu Y; Hu M; Li X; Aodengqimuge ; Ma Y; Wei C; Song L
    Cancer Sci; 2015 Aug; 106(8):1023-32. PubMed ID: 26041409
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Amurensin G, a potent natural SIRT1 inhibitor, rescues doxorubicin responsiveness via down-regulation of multidrug resistance 1.
    Oh WK; Cho KB; Hien TT; Kim TH; Kim HS; Dao TT; Han HK; Kwon SM; Ahn SG; Yoon JH; Kim TH; Kim YG; Kang KW
    Mol Pharmacol; 2010 Nov; 78(5):855-64. PubMed ID: 20713551
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The role of long non-coding RNA H19 in breast cancer.
    Wang J; Sun J; Yang F
    Oncol Lett; 2020 Jan; 19(1):7-16. PubMed ID: 31897110
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The regulatory roles of long non-coding RNAs in the development of chemoresistance in breast cancer.
    Malhotra A; Jain M; Prakash H; Vasquez KM; Jain A
    Oncotarget; 2017 Dec; 8(66):110671-110684. PubMed ID: 29299178
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Circulating lncRNA H19 in plasma as a novel biomarker for breast cancer.
    Zhang K; Luo Z; Zhang Y; Zhang L; Wu L; Liu L; Yang J; Song X; Liu J
    Cancer Biomark; 2016 Jun; 17(2):187-94. PubMed ID: 27540977
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Drug resistant breast cancer cells overexpress ETS1 gene.
    Kars MD; Işeri OD; Gündüz U
    Biomed Pharmacother; 2010 Sep; 64(7):458-62. PubMed ID: 20392592
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long Non-coding RNA H19 Recruits NFYB to Activate MBTD1 and Regulate Doxorubicin Resistance in Lymphoma Cells.
    Feng L; Yan Q; Xu X
    Mol Biotechnol; 2023 Jun; 65(6):997-1009. PubMed ID: 36434485
    [TBL] [Abstract][Full Text] [Related]  

  • 36. TBX15/miR-152/KIF2C pathway regulates breast cancer doxorubicin resistance via promoting PKM2 ubiquitination.
    Jiang CF; Xie YX; Qian YC; Wang M; Liu LZ; Shu YQ; Bai XM; Jiang BH
    Cancer Cell Int; 2021 Oct; 21(1):542. PubMed ID: 34663310
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Aldo-keto reductase 1C3 (AKR1C3) is associated with the doxorubicin resistance in human breast cancer via PTEN loss.
    Zhong T; Xu F; Xu J; Liu L; Chen Y
    Biomed Pharmacother; 2015 Feb; 69():317-25. PubMed ID: 25661377
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of MDR1 phosphorothioate antisense oligodeoxynucleotides in multidrug-resistant human tumor cell lines and xenografts.
    Ramachandran C; Wellham LL
    Anticancer Res; 2003; 23(3B):2681-90. PubMed ID: 12894558
    [TBL] [Abstract][Full Text] [Related]  

  • 39. H19 mediates methotrexate resistance in colorectal cancer through activating Wnt/β-catenin pathway.
    Wu KF; Liang WC; Feng L; Pang JX; Waye MM; Zhang JF; Fu WM
    Exp Cell Res; 2017 Jan; 350(2):312-317. PubMed ID: 27919747
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Role of FoxO1 activation in MDR1 expression in adriamycin-resistant breast cancer cells.
    Han CY; Cho KB; Choi HS; Han HK; Kang KW
    Carcinogenesis; 2008 Sep; 29(9):1837-44. PubMed ID: 18390843
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.